44104 Effectiveness of Ixekizumab in psoriasis patients previously treated with other IL-17 pathway inhibitors

Background: Introduction: Inhibitors of the IL-17 pathway are therapeutic agents whose efficacy and safety in moderate-to-severe psoriasis have been demonstrated in clinical trials. Ixekizumab is a humanized anti-IL17A monoclonal antibody. We herein report our experience in the effectiveness of ixekizumab in a series of patients with moderate-to-severe psoriasis and a history of past treatment with other anti-IL17 agent(s) (secukinumab, brodalumab).